FDA spurns J&J's trou­bled rheuma­toid arthri­tis drug sirukum­ab

J&J $JNJ played this one straight out to the end, but af­ter an over­whelm­ing­ly neg­a­tive ex­pert pan­el vote against an ap­proval of its trou­bled rheuma­toid arthri­tis drug sirukum­ab, the FDA has for­mal­ly re­ject­ed the mar­ket­ing ap­pli­ca­tion — omi­nous­ly de­mand­ing more da­ta for re­view.

J&J said af­ter the mar­ket closed Fri­day that it will study the sit­u­a­tion on this drug, which some an­a­lysts once count­ed as a like­ly block­buster-to-be.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.